NCT00000691View on ClinicalTrials.gov

A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

Not specified

Study Completion Date

August 31, 1992

Conditions
Cytomegalovirus RetinitisHIV Infections
Interventions
DRUG

Foscarnet sodium

Trial Locations (11)

10016

NY Univ. HIV/AIDS CRS, New York

10021

Cornell University A2201, New York

14215

SUNY - Buffalo, Erie County Medical Ctr., Buffalo

14642

Univ. of Rochester ACTG CRS, Rochester

21287

Johns Hopkins Adult AIDS CRS, Baltimore

27710

Duke Univ. Med. Ctr. Adult CRS, Durham

33136

Univ. of Miami AIDS CRS, Miami

90033

USC CRS, Los Angeles

94114

Ucsf Aids Crs, San Francisco

02114

Massachusetts General Hospital ACTG CRS, Boston

Unknown

Washington U CRS, St Louis

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000691 - A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure | Biotech Hunter | Biotech Hunter